DPhG Jahrestagung 2014

Frankfurt, 23.9. bis 26.9.

Chairman
Dieter Steinhilber

Vice Chairman
Manfred Schubert-Zsilavecz

Scientific Organizing Committee
Stefan Laufer, Andreas Link, Olaf Queckenberg, Christoph Friedrich, Peter Gmeiner, Jochen Klein, Peter Langguth, Kristina Leuner, Angelika Vollmar, Hermann Wätzig, Thomas Efferth, Ulrike Holzgrabe, Ulrich Jaehde, Heyo Kroemer, Irmgard Merfort, Klaus Mohr, Peter Ruth, Andrea Sinz, Werner Weitschies, Gerhard Winter

Local Organizing Committee
Theo Dingermann, Jennifer Dressman, Gunter Eckert, Robert Fürst, Ann-Kathrin Häfner, Michael Karas, Thorsten Maier, Rolf Marschalek, Eugen Proschak, Bettina Hofmann, Bernd Sorg, Michael Stein, Mario Wurglics

	Dienstag, 23.9.2014		
	Bürgersymposium: Frankfurter Pharmaziegeschichte - Von Goethe bis Hoechst • Ort: Campus Westend (Foyer PA Gebäude)	**Advanced Course in Pharmacology (DGPT) 'Durchflusszytometrie: Anwendungen in pharmakologischer und pharmazeutischer Forschung** Separate Anmeldung bei der DGPT erforderlich • Ort: OSZ (HS 3) **15.00-18.30 Uhr**	**Workshop Drittmittelförderung** • Ort: OSZ (HS 4)
15.00-15.15 Uhr	**Begrüßung**, Christoph Friedrich, Marburg	**15:00-15:10: Einführung,** Prof. Dr. Detlef Neumann	**14.00 -16.00: Dos und Don'ts beim Antragschreiben** , T. Hotopp, DFG
15.15-16.00 Uhr	**Zur Entwicklung der Pharmazie an der Johann-Wolfgang-Goethe-Universität Frankfurt,** Prof. Dr. Axel Helmstädter	**15:10-15:55: Einführung in die Durchflusszytometrie,** Dr. Stefan Schnell **'Next generation' Fluoreszenz-aktiviertes Zellsortieren mithilfe der Mikrochip-Technologie**, Dr. Martin Büscher	**16.00-17.00: Horizon 2020,** M. Ackermann, Nationale Kontaktstelle Lebenswissenschaften
16.00-16.45 Uhr	**Zur Geschichte des Frankfurter Apothekenwesens,** Dr. Caroline Seyfang	**15:55-16:40: Durchflusszytometrie für die pharmakologische Charakterisierung von GPCR Liganden**, Prof. Dr. Erich Schneider	
16.45-17.15 Uhr	**Kaffeepause**	**16:40-17:00: Kaffeepause**	**15.00-16.30: Beiratssitzung des VdPPhI** • Ort: OSZ (HS5)
17.15-18.00 Uhr	**Die Entwicklung der Firma Hoechst unter besonderer Berücksichtigung ihrer Geschichte im Dritten Reich**, Prof. Dr. Stephan H. Lindner	**17:00-17:45: Chipzytometrie für die 'high-content' zelluläre Biomarker-Analyse: Technologie und Anwendung**, Dr. Christian Hennig	**17:00-19:30: Mitgliederversammlung des VdPPhI** • Ort: OSZ (HS 5)

18.00-18.45 Uhr	**Eine Tradition der besonderen Art: Goethe und sein Verhältnis zur Pharmazie und zu Pharmazeuten,** Prof. Dr. Christoph Friedrich	**17:45-18:30: Standardisierung und Automatisierung durchflusszytometrischer Assays in der pharmakologischen Forschung,** Dr. Peter Engel	
	anschl. Empfang, Campus Westend, Foyer PA Gebäude		

	Wednesday, 24.9.2014 **Fachgruppen-Meetings**				
	OSZ H2	**OSZ H3**	**OSZ H4**	**OSZ H5**	**OSZ H6**
9.00-10.30	**Pharmazie 2020,** D. Steinhilber, S. Laufer				
10.30-12.00	**Fachgruppe Pharm./Med. Chemie,** P. Gmeiner	**Fachgruppe Pharmakologie,** J. Klein	**Fachgruppe Klinische Pharmazie,** K. Friedland	**Fachgruppe Pharm. Biologie,** A. Vollmar	**Fachgruppe Pharm. Technologie,** P. Langguth

	Wednesday, 24.9.2014 **Main Symposium (Congress language English)**
13.00-13.30 OSZ, H1/H2	**Opening of the Annual DPhG Meeting 2014,** **Trends and Perspectives in Pharmaceutical Sciences**
13.30-14.15 OSZ, H1/H2	**PL 1, Peter Ruth**, New disease relevant functions of Ca^{2+}-activated potassium channels (OSZ H1+2)
14.15-15.00 OSZ, H1/H2	**PL 2, Shinji Yamashita,** Streamlining the development of oral drug product: Role of researchers in academia (OSZ H1+2)
15.00-15.30 OSZ	Coffee break

	Short talks, parallel sessions I		
15.30-17.00	**OSZ H3**	**OSZ H4**	**OSZ H5**
	Antiinflammatory Drugs **Chair: S. Laufer, D. Steinhilber**	**Neurodegeneration** **Chair: C. Culmsee, J. Klein**	**Pharmaceutical Technology and Drug Delivery** **Chair: L. Meinel, W. Weitschies**
	15:30 Jan Schwab, Resolvins, protectins and maresins as candidates to propagate resolution of inflammation in lesions of the central nervous system (CNS)	**15:30 Carsten Culmsee,** Molecular stroke research: New insights into Bid-mediated mitochondrial demise in neuronal cell death.	**15:30 Markus Thommes**, Formulation strategies for poorly water soluble drugs.
	15:50 Andreas Köberle, Functional lipidomics reveals phosphatidylcholine-bound arachidonic acid as regulator of protein kinase B.	**15:55 Jochen Klein**, Experimental stroke research: Neuroprotection by dietary and Ginkgo constituents in animal models.	**15:50 Stephan Reichl**, Valid cell culture models of the human cornea for drug transport investigations - where are we?
	16:10 Thorsten Maier, Nitro lipids as novel regulators of leukotriene biosynthesis.	**16:20 Carina Hohmann**, Clinical stroke research: Emerging options for pharmaceutical care in stroke patients.	**16:10 Tessa Charlotte Lühmann**, Bioresponsive protein delivery.
	16:30 Olivia Merkel, Ex vivo and in vivo siRNA delivery to activated T cells as novel anti-inflammatory asthma therapy	**16:40 Amalia Dolga**, SK channel modulation attenuates mitochondrial dysfunction, neuroinflammation, and neuronal cell death	**16:30 Anne Seidlitz**, In vitro estimation of drug transfer from paclitaxel-coated balloon catheters
	16:45 Christoph Schmidt, Rational protein-engineering yields a minimised innate immune inhibitor with unique targeting properties		**16:45 Miriam Pein**, Self-developed sensor membranes for etongue sensors
17.00-18.00 OSZ H1/2	**Short lectures (5 min)**		
	Hayato Fukuda, Design, synthesis and biological evaluation of a stabilized resolvin E2 analogue **Yudai Matsuda**, Biosynthetic studies on fungal meroterpenoids and their fascinating chemistry **Masahito Yoshida**, Destruxin E, a potent negative regulator of osteoclast morphology: Solid-phase library synthesis and biological evaluation **Tsuyoshi Saitoh**, Design and synthesis of NF-κB inhibitors carring epoxyquinol moiety **N.N. (PSJ, Osaka)** **N.N. (PSJ, Osaka)** **N.N. (PSJ, Osaka)** **Marlene Barho**, Structure-activity relationship studies on small molecule Bid-inhibitors		

	Anna Junker, Synthesis and structure affinity relationships of dual chemokine receptor 2 and chemokine receptor 5 antagonists and development of a selective, fluorinated CCR2 ligand for PET studies **Ann-Kathrin Schoenfeld**, Testing of potential inhibitors of human heparanase in a fluorescence activity assay **Rico Schwarz**, Monitoring conformational changes in PPARβ/δ by cross-linking and mass spectrometry **Wenjin Li**, A dynamic pH junction method for monitoring the catalytic activity of cerebroside sulfotransferase **Dominique Lunter**, Confocal Raman microscopic (CRM) methodology for the analysis of the penetration of pharmaceutical actives into the skin **Julian Schichtel**, Determination of the dissolution behaviour of celecoxib-Eudragit E 100-nanoparticles using cross-flow filtration **Verena Gotta**, Sensitivity of concentration-effect versus dose-effect analysis to detect small magnitudes of QTc prolongation in preclinical cardiovascular safety setting	
18.00-22.00 OSZ	**Poster session I** and welcome reception	**18.00-18.30 Außerordentliche Hauptversammlung der DPhG** (OSZ H3)

	Thursday, 25.9.2014		
8.30-9.15 OSZ, H1/H2	**PL 3, Rolf Hartmann,** Interference with bacterial quorum sensing: a new antivirulence strategy (OSZ H1+2)		
9.15-10.00 OSZ, H1/H2	**Nagayoshi Nagai Lecture, Masakatsu Shibasaki (PSJ),** Recent progress in cooperative asymmetric catalysis (OSZ H1+2)		
10.00-10.30 OSZ	Coffee break		
	Short talks, parallel sessions II		
10.30-12.00	**OSZ H3**	**OSZ H4**	**OSZ H5**
	Medicinal Chemistry (PSJ) **Chair: N. Miyata, K. Tomioka**	**Biomarker and Modeling** **Chair: C. Kloft, T. Lehr.**	**Ligand Binding Assays** **Chair: C. Müller, H. Wätzig**
	10:30 Kiyoshi Tomioka, Paradigm re-shift of medicinal chemistry in Japan	**10:30 Markus Joerger,** Implementation of dosing algorithms of anticancer drugs based on pharmacological biomarkers	**10:30 Frank M. Boeckler,** Biophysical techniques in fragment hit identification and lead optimization - A change of perspective?
	10:55 Naoki Miyata, Design, synthesis and biological activity of lysine-specific demethylase (KDM) inhibitors	**11:00 Thorsten Lehr,** Mathematical modeling of amyloid beta for the diagnosis and treatment of Alzheimer's disease	**10:50 Christian Kramer,** The impact of experimental uncertainty on decision making in drug design
	11:20 Hiroshi Nagase, Synthesis of a novel	**11:30 Rolf Burghaus,** Understanding	**11:20 Dominique Bonnet**, Fluorescent probes

	opioid receptor agonist, SYK-146 with 1,3,5-trioxazatriquinane skeleton and its pharmacologies	coagulation biomarkers and deriving clinically relevant surrogates by use of an in-silico coagulation model		to track GPCR binding and dimerization
	11:45 Hiroaki Ohno, Gold-catalyzed annulations and their medicinal applications			**11:40 Yosuke Taniguchi**, Development of triplex-forming oligonucleotide having artificial nucleoside analogues to inhibit the gene expression as an antigene strategy
12.00-13.30 OSZ	**Poster Session II** and lunch break			
	Short talks, parallel sessions III			
13.30-15.00	**OSZ H3**	**OSZ H4**	**OSZ H5**	**OSZ H6**
	Computational Chemistry and Molecular Design. Chair: F. Böckler, O. Koch	**Natural Compounds Chair: R. Fürst, A. Vollmar**	**Analytics II Chair: M. Karas, A. Sinz**	**Case studies from Pharmaceutical Research and Development Chair: B. Cezanne, N.N.**
	13:30 Andreas Bender, Integrating chemical and biological data for drug design and mode-of-action analysis	**13:30 Verena Dirsch**, Neolignans: from PPARγ to RXRα	**13:30 Dietrich Volmer**, Analysis of vitamin D metabolic markers by mass spectrometry: Advantages and limitations of the gold standard method	**13:30 Andrea Hanefeld**, Drug delivery for therapeutic cancer vaccination
	13:45 Steve Maginn, A knowledge-based approach to assessing propensity for polymorphism in the pharmaceutical crystalline solid form	**13:50 Andreas Bechthold**, Waking up biosynthetic gene clusters in a row	**13:50 Andreas Roempp**, High resolution MALDI imaging: Reliable molecular identification at cellular resolution	**13:50 Christoph Saal**, Selection of solid state forms for new chemical entities: Challenges, opportunities, adventures and lessons learned
	14:00 Thomas Exner, Direct integration of ligand-based NMR data into protein-ligand docking	**14:10 Jennifer Hermann and Florian Förster**, Chondramides: setting the stage for actin binding compounds in cancer therapy	**14:10 Kai Scheffler**, Mass spectrometric characterization of biopharmaceuticals - possibilities, challenges and limitations	**14:10 Matthias Winzer**, Fast track formulation development for biotherapeutics
	14:15 Alexander Dömling, Targeting PPIs with	**14:30 Johanna Liebl**, Cdk5 inhibition potentiates imatinib	**14:30 Ganna Kalayda**, Fluorescent oxaliplatin analogue as a model for	**14:30 Sonja Skopp**, Fighting schistosoiasis in young children:

	AnchorQuery™	responsiveness of Philadelphia chromosome positive chronic myeloid leukemia cells	the anticancer drug oxaliplatin for the investigation of its cellular trafficking	The Pediatric Praziquantel Consortium
	14:30 Holger Gohlke, Identification of a mechanism-of-action target exploiting similarities of chemotypes and signalling events, and biophysical simulations	**14:45 Finn Hansen**, Plasmodium falciparum histone deacetylases (PfHDACs) as epigenetic drug targets	**14:45 Christian Wischke**, A polymeric multifunctional glaucoma implant	**14:50 Steffen Lüdeke**, Chirality in polyketide antibiotics: substrate-dependent inversion of stereoselectivity in Tyl-KR1-catalyzed reductions
	14:45 Discussion			
15.00-15.30 OSZ	Coffee break			
	Short talks, parallel sessions IV			
15.30-17.00	**OSZ H3**	**OSZ H4**	**OSZ H5**	
	GPCR Medicinal Chemistry **Chair: P. Gmeiner, U. Holzgrabe**	**Industrial Pharmacy** **Chair: A. Link, S. Schmidt**	**Biopharmaceutics and Pharmaceutical Technology** **Chair: P. Langguth, S. Yamashita**	
	15:30 Armin Buschauer, Toward selective molecular tools for histamine receptor subtypes: conformational constraints, bioisosteric and bivalent approaches	**15:30 Norbert Nagel**, Biophysical characterization of pharmaceutical peptides	**15:30 Heinrich Haas**, Formulation of RNA pharmaceuticals	
	16:00 Gerhard Wolber, Modulation of GPCR signaling: Understanding ligand binding effects	**15:50 Carsten Olbrich**, Subvisible particles in protein formulations	**15:50 Herbert Wachtel**, Automatized testing of inhalation devices in early development phase	
	16:20 Michael Decker, Molecular combination of GPCR ligands: bivalent, hybrid and dualsteric compounds	**16:10 Harry F. Abts**, Dissecting pharmacodynamic action of compound mixtures by use of in vitro models	**16:10 Peter Serno**, Orodispersible dosage forms	
	16:40 Nuska Tschammer, Boronic acids as probes for exploration of allosteric regulation of the chemokine receptor CXCR3	**16:30 Uwe Muenster**, Current biopharmaceutics prediction tools - an overview	**16:30 Mai Anh Nguyen**, Pharmacokinetic drug – neutraceutical interactions: A particular type of food - drug interaction	
			16:45 Thomas Nawroth, Gastro-intestinal simulator for in-vitro drug and nanoparticle tracing in oral drug development	

	Short talks, parallel sessions V		
17.00-18.30	**OSZ H3**	**OSZ H4**	**OSZ H5**
	Anticancer and Epigenetic Drugs **Chair: C. Brandts, R. Marschalek**	**Evidence-based Medication Management** **Chair: K. Friedland, U. Jaehde**	**Optimizing Oral Drug Performance** **Chair: M. Brewster, J. Dressman**
	17.00 Tom Milne, Unraveling the aberrant epigenetic programming of MLL leukemias	**17.00** Welcome and short introduction	**17:00 Marcus Brewster**, „of springs and parachutes" – improving oral bioavailability
	17.30 Stefan Fröhling, Identifying therapeutic targets in MLL fusion-driven leukemia using functional genomics	**17.10 Isabel Waltering, Susanne Koling, Georg Hempel**, Patients in community pharmacies	**17:30 Mathew Leigh**, assessing the gastrointestinal „Spring" effect – the media
	18.00 Rolf Marschalek, MLL leukemias and future treatment strategies	**17.30 Anne Pauly, Carolin Wolf, Kristina Friedland**, Psychiatric patients	**17:50 Edmund Kostewicz**, will the parachute crash? – transfer models for assessing performance of optimized formulations
	18:15 Manfred Jung, Selective Sirt2-inhibition by ligand induced rearrangement of the active site	**17.50 André Wilmer, Ulrich Jaehde**, Patients in oncology	**18:10 Rodrigo Cristofoletti**, connecting oral formulation performance to therapeutic effect
		18.10 Anna Laven, PHARMAGRIPS: Structured pharmaceutical counseling in the self-medication of the common cold. A randomised controlled study (RCT)	
		18.20 Discussion	
19.30	**Conference dinner**		

	Friday, 26.9.2014
8.30-9.15 OSZ, H1/H2	**PL 5, Charlotte Kloft,** Pharmacometrics for better therapies? (OSZ H1+2)
9.15-10.00 OSZ, H1/H2	**PL 6, Ernst Wagner**, Sequence-defined carriers for targeted intracellular drug and nucleic acid delivery (OSZ H1+2)
10.00-10.30 OSZ	Coffee break
	Short talks, parallel sessions VI

10.30-12.00	OSZ H3	OSZ H4	OSZ H5
	Multitarget Drugs **Chair: T. Efferth, E. Proschak**	**Non-canonical GPCR-Signaling** **Chair: C. Hoffmann, K. Mohr**	**Biopharmaceuticals/Biotechnology** **Chair: O. Germershaus, E. Wagner**
	10:30 Jens-Uwe Peters, An introduction to polypharmacology in drug discovery	**10:30 Andreas Bock**, Dynamic ligand binding"	**10:30 Hanns-Christian Mahler**, major trends and challenges in biotherapeutic product development: "polysorbate degradation" and "drug-device combination product development"
	11:00 Thomas Efferth, Multifactorial activity of the naphthoquinone shikonin against cancer cells	**10:50 Andreas Rinne**, Voltage-dependent GPCR-activation	**10:50 Michael Siedler**, Finding the right candidate – integrated lead ID of next-generation molecules
	11:15 Eugen Proschak, Polypharmacology: In silico recognition vs. rational design	**11:10 Michael Mederos y Schnitzler**, Mechanosensitivity of histamine H_1 receptor	**11:10 Carsten Rudolph**, non-immunogenic messenger RNA therapeutics
	11:30 Samuel N. Okpanyi, Study of the anxiolytic actions of Valeriana officinalis L., Melissa officinalis L., Passiflora incarnata L. and their combination STW 32 in experimental models of anxiety	**11:30 Annette Kaiser**, Signaling in malaria parasites: A non-canonical G-protein from plasmodium falciparum	**11:30 Leonard Kaysser**, Divergent pathways for the biosynthesis of merochlorins, cyclic meroterpenoid antibiotics from a marine streptomycete
	11:45 Olaf Kelber, Motility modulation beyond MCP: Mechanisms of action of a clinically proven herbal medicinal product, STW 5, in functional GI diseases	**11:45 N.N.** selected from abstracts	**11:45 Arnold Grünweller**, Combination strategies for targeting the oncogenic Pim1 kinase
12.00-13.00 OSZ	Short Lunch break		
13.00-13.45 OSZ H1/H2	**PL 7, Zoltan Takats, London,** Direct mass spectrometric characterization of biological tissues - from automated histology to DMPK studies (OSZ H1+2)		
14.00-15.00 OSZ H1/H2	**Closing ceremony, (OSZ H1+2)**		

Samstag, 27.9.2014

Tag der Offizinpharmazie
Organizing Committee
Kathrin Müller, Annegret Birr, Erika Fink, Michael Hannig, Juliane Kresser
(LAK Hessen und DPhG FG Allgemeinpharmazie)

Veranstaltungsort: Otto-Stern-Zentrum, HS2, Goethe Universität,
Ruth-Moufang-Straße 2, 60438 Frankfurt am Main

Personalisierte Pharmakotherapie

14:30 – 15:30 Uhr	**Interaktionen - Welche sind häufig und relevant** **Dr. Nina Griese-Mammen** Zentrum für Arzneimittelinformation und Pharmazeutische Praxis (ZAPP) der ABDA, Berlin
15:30 – 16:00 Uhr	Kaffeepause
16:00 – 17:00 Uhr	**Patientenorientierte Arzneimitteltherapie: Ein Starter** **Prof. Theo Dingermann** Institut für Pharmazeutische Biologie, Frankfurt am Main
17:00 – 18:00 Uhr	**Einfluss genetischer Variabilität auf die Wirkung von Arzneimitteln** **Prof. Dr. Manfred Schubert-Zsilavecz** Institut für Pharmazeutische Chemie, Frankfurt am Main
Moderation:	**Prof. Dr. Dieter Steinhilber** Sprecher der Akademie für Pharmazeutische Fortbildung der LAK Hessen
18:00 Uhr	**Mitgliederversammlung der Fachgruppe Allgemeinpharmazie**